Eli Lilly (NYSE:LLY) announced agreements to acquire three vaccine development companies for a combined potential value of up to $3.83 billion in cash.
The companies are Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. The move expands Lilly's infectious disease R&D.
Curevo shareholders could receive up to $1.5 billion, LimmaTech up to $780 million, and Vaccine Company up to $1.55 billion.
Daniel Skovronsky, Lilly's chief scientific officer, said: "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences."
